RHODE ISLAND, UNITED STATES /
vu.RHODE ISLANDTHE LOCAL PERSPECTIVE
Partner with Vu ↗
← All stories

THE LOCAL PERSPECTIVE

Medical Advances To Watch In 2014

Medical Advances To Watch In 2014

1. Na-Nose can detect lung cancer from exhaled breath and will be commercialized in a joint venture with Boston-based Alpha Szenszor – after a few more years of development and testing by the US Food and Drug Administration (FDA). Invented by Technion Prof. Hossam Haick, Na-Nose (the “na” is for “nanotechnology”) has been proven in numerous international clinical trials to differentiate between different types and classifications of cancer with up to 95 percent accuracy.

2. Hervana non-hormonal, long-acting contraceptive suppository won a $1 million development grant last year from the Bill & Melinda Gates Foundation. The Gates Foundation is banking on the product’s potential to provide a more accessible, cheaper and socially acceptable family planning option in developing countries, though it would be marketed in the United States and Europe as well.

3. Vecoy Nanomedicines nano-scale virus-traps (“vecoys”) capture and destroy viruses before they can infect cells, offering a huge advance over antiviral medications and even vaccines. Through the MassChallenge startup accelerator program last November, Vecoy’s platform was chosen to be tested in zero-gravity conditions on an upcoming NASA space mission.

4. CartiHeal Agili-C cartilage regeneration solution for knees can regenerate true hyaline cartilage (the most abundant type of cartilage in the human body) after six months, according to clinical results so far. Based on research at Ben-Gurion University of the Negev, the implant has earned the European Union’s CE Mark of approval. Further clinical studies could lead to FDA approval in the coming years.

5. Oramed Pharmaceuticals seeks to change Type 2 diabetes treatment from a daily injection to a daily pill. Its oral insulin capsule recently received patent approval in the EU, and is in Phase 2 clinical trials under an Investigational New Drug application with the FDA. Jerusalem-based Oramed is also moving forward with clinical trials of a capsule to treat Type 1 diabetes.

6. Premia Spine developed the TOPS (Total Posterior Solution) System, aiming to revolutionize the spinal implant market with an artificial joint in the same way that total hip and total knee replacement systems made hip and knee fusions a thing of the past. TOPS is available already in Austria, Germany, the UK, Turkey and Israel. An FDA study is now in the follow-up phase.

7. Mapi Pharma recently won US patents for two promising slow-release platforms for drugs to treat multiple sclerosis symptoms and pain. “We believe in two to three years they could be in the final stage of development, and about three years to market,” says Mapi Pharma president and CEO Ehud Marom. Another slow-release platform for a schizophrenia drug is next in the pipeline.

8. Discover Medical introduced the SomnuSeal mask for CPAP machines – used widely by sufferers of sleep apnea – in Europe. If sales are successful, the US market will be next. Because SomnuSeal is more comfortable than the current masks used with the machine, compliance could be much greater. Plus, the device does not put strain on the heart as the current mask does.

9. Real Imaging is in the midst of European clinical trials of RUTH, its radiation-free, contact-free, inexpensive and advanced imaging system for early detection of breast cancer. The system, which has won patent approvals in several countries, analyzes 3D and infra-red signals emitted from cancerous and benign tissue, generating an objective report that needs no interpretation. Founder and CTO Boaz Arnon presented RUTH at the most recent conference of the Radiological Society of North America. Initial release of the product will likely be in Europe sometime in 2015.

10. NeuroQuest has started clinical testing in the United States, under the auspices of Harvard Clinical Research Institute, for its groundbreaking blood test to detect early-stage Alzheimer’s disease. Initial trials in Israel showed NeuroQuest’s test – based on research by Prof. Michal Schwartz of the Weizmann Institute of Science – to be 87 percent accurate with an 85% specificity rate in detecting Alzheimer’s and ALS, two common neurodegenerative diseases.

Article Source: http://israel21c.org/headlines/top-10-israeli-medical-advances-to-watch-in-2014/

Other Articles Of Interest:
Medical Advances To Watch In 2014
Why Are The Chinese Controlling The Rain
Why Do Koalas Hug Trees?
Young Illegal Immigrants Can Defer Deportation
Illegal Immigrants Are Being Shipped To Arizona 
Why Are Mega-Mergaers Killing Innovation?
D-Day Invasion


Other Videos Of Interest:
Naples Plastic Surgery
Naples Dentist
Real Estate Video Marketing
Video Marketing Services
Naples Web Design
Naples SEO
Naples Real Estate

© 2014 all rights reserved

THE READING ROOM

Find your next read.

Good stories. A few ways in.

View the full archive ↗

YOUR NEXT MOVE · Rhode Island REAL ESTATE

A new chapter.
A local conversation.

Buying, selling, or simply weighing your options? Start with what matters to you, then connect with Ron Abboud to discuss the next step.

01 / BUYING

Find your place.

Explore homes, share your preferred area and timing, and begin a conversation about your search.

Browse existing listings ↗
02 / SELLING

Plan what’s next.

Thinking about selling? Outline your property and goals, and discuss your options with Ron.

Prefer a conversation? Call Ron ↗
RA
Connect with Ron AbboudStart with your goals. Take the next step together.
239-228-9300

OUR PERSPECTIVE

A place is more than
a pin on a map.

It’s the conversations at a neighborhood gathering. The questions before buying a home. The ideas that help a local business move forward.

Vu Rhode Island brings those perspectives together—from community stories and real estate to business, technology, and wellness.

RARon AbboudPublisher, Vu Rhode Island↗

GOOD QUESTIONS. CLEAR ANSWERS.

A little more about Vu.

What does Vu Rhode Island cover?+

Community conversations, real estate, business and AI, and wellness in Rhode Island and beyond. Browse by topic above or search the stories.

How can my business partner with Vu?+

Start a conversation about your audience, goals, and timing. Proposed options include display placements, clearly labeled sponsored stories, and category partnerships. Final availability and terms are confirmed individually.

Can I share a story idea?+

Yes. Call 239-228-9300 to discuss a local story, community conversation, or potential interview.

YOUR NEXT MOVE

Let’s find your
starting point.

A few details make the conversation more useful.

I’m interested in

Your email app will open with these details. Send the message there to reach Ron; you can also call directly.

LET’S START A CONVERSATION

A partnership
with purpose.

Choose the format you’d like to explore, then email your brief directly to Ron.